|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/15/20 U.S. NeuroSurgical Holdings, Inc. 10-Q 3/31/20 39:3.4M Broadridge Fin’l So… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 266K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
27: R1 Document and Entity Information HTML 43K
13: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 101K
17: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 23K
(Parenthetical)
38: R4 Condensed Consolidated Statements of Operations HTML 55K
(Unaudited)
29: R5 Condensed Consolidated Statements of Cash Flows HTML 96K
(Unaudited)
14: R6 Basis of Preparation HTML 64K
18: R7 Gamma Knife at NYU Medical Center HTML 19K
39: R8 The Southern California Regional Gamma Knife HTML 42K
Center
26: R9 Florida Oncology Partners HTML 51K
33: R10 Boca Oncology Partners HTML 41K
31: R11 Medical Oncology Partners HTML 44K
10: R12 CB Oncology Partners HTML 42K
21: R13 Income Taxes HTML 16K
34: R14 Basis of Preparation (Tables) HTML 58K
32: R15 The Southern California Regional Gamma Knife HTML 40K
Center (Tables)
11: R16 Florida Oncology Partners (Tables) HTML 42K
22: R17 Boca Oncology Partners (Tables) HTML 40K
35: R18 Medical Oncology Partners (Tables) HTML 42K
30: R19 CB Oncology Partners (Tables) HTML 41K
15: R20 Basis of Preparation (Details) HTML 94K
19: R21 Gamma Knife at NYU Medical Center (Details) HTML 21K
36: R22 The Southern California Regional Gamma Knife HTML 100K
Center (Details)
24: R23 Florida Oncology Partners (Details) HTML 154K
16: R24 Boca Oncology Partners (Details) HTML 102K
20: R25 Medical Oncology Partners (Details) HTML 99K
37: R26 CB Oncology Partners (Details) HTML 83K
25: R27 Income Taxes (Details) HTML 19K
23: XML IDEA XML File -- Filing Summary XML 64K
28: EXCEL IDEA Workbook of Financial Reports XLSX 37K
4: EX-101.INS XBRL Instance -- usnu-20200331 XML 890K
6: EX-101.CAL XBRL Calculations -- usnu-20200331_cal XML 135K
7: EX-101.DEF XBRL Definitions -- usnu-20200331_def XML 421K
8: EX-101.LAB XBRL Labels -- usnu-20200331_lab XML 869K
9: EX-101.PRE XBRL Presentations -- usnu-20200331_pre XML 612K
5: EX-101.SCH XBRL Schema -- usnu-20200331 XSD 97K
12: ZIP XBRL Zipped Folder -- 0001140361-20-011787-xbrl Zip 103K
| 1. |
I have reviewed this Report on Form 10-Q of U.S. NeuroSurgical Holdings, Inc.;
|
| 2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
| 3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
| 4. |
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
|
| a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
|
| b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
| c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report my conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and
|
| d) |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and;
|
| 5. |
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of
directors (or persons performing the equivalent functions):
|
| a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant’s ability to record, process, summarize and report financial information; and
|
| b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
Date: May 15, 2020
|
/s/ Alan Gold
|
|
President & Chairman of the Board
|
|
|
(Principal Executive Officer
|
|
|
and Principal Financial
|
|
|
Officer)
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/15/20 | None on these Dates | ||
| For Period end: | 3/31/20 | |||
| List all Filings | ||||